Press coverage about Paratek Pharmaceuticals (NASDAQ:PRTK) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Paratek Pharmaceuticals earned a news sentiment score of 0.20 on Accern’s scale. Accern also gave media headlines about the specialty pharmaceutical company an impact score of 47.0710364202768 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the media stories that may have effected Accern’s scoring:
- Paratek Pharmaceuticals: The Realistic Case For Omadacycline – Seeking Alpha (seekingalpha.com)
- Trading summary of Watch List stock – Paratek Pharmaceuticals, Inc. (PRTK) – Wall Street Morning (wallstreetmorning.com)
- FY2018 EPS Estimates for Paratek Pharmaceuticals Inc (PRTK) Raised by Analyst (americanbankingnews.com)
- Paratek Pharmaceuticals (PRTK) Given “Outperform” Rating at Leerink Swann (americanbankingnews.com)
- Paratek Pharmaceuticals Inc (PRTK) to Post Q1 2018 Earnings of ($0.92) Per Share, Leerink Swann Forecasts (americanbankingnews.com)
PRTK has been the subject of a number of recent research reports. ValuEngine cut shares of Paratek Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. HC Wainwright increased their target price on shares of Paratek Pharmaceuticals from $43.00 to $55.00 and gave the company a “buy” rating in a research report on Friday, March 2nd. Zacks Investment Research upgraded shares of Paratek Pharmaceuticals from a “hold” rating to a “buy” rating and set a $18.00 target price for the company in a research report on Tuesday, January 23rd. Cantor Fitzgerald set a $50.00 target price on shares of Paratek Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, January 3rd. Finally, UBS Group cut shares of Paratek Pharmaceuticals from a “strong-buy” rating to an “outperform” rating in a research report on Friday, March 2nd. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $40.75.
Paratek Pharmaceuticals (NASDAQ:PRTK) last issued its earnings results on Thursday, March 1st. The specialty pharmaceutical company reported ($0.78) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.75) by ($0.03). Paratek Pharmaceuticals had a negative net margin of 706.00% and a negative return on equity of 93.16%. The business had revenue of $5.07 million during the quarter, compared to analyst estimates of $5.00 million. equities research analysts expect that Paratek Pharmaceuticals will post -3.39 earnings per share for the current fiscal year.
In related news, Director Robert S. Radie sold 3,000 shares of the firm’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $14.22, for a total transaction of $42,660.00. Following the completion of the sale, the director now directly owns 9,330 shares in the company, valued at $132,672.60. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Douglas W. Pagan sold 16,291 shares of the firm’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $14.22, for a total transaction of $231,658.02. Following the sale, the chief financial officer now owns 39,570 shares of the company’s stock, valued at $562,685.40. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 40,664 shares of company stock valued at $573,226. 4.90% of the stock is owned by company insiders.
Paratek Pharmaceuticals Company Profile
Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.